NCT06558708View on ClinicalTrials.gov

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Type 2 Diabetes
Interventions
DRUG

GZR101 Injection

Once daily

DRUG

GZR33 Injection

Once daily

DRUG

Insulin aspart

Once daily

Trial Locations (1)

Unknown

RECRUITING

Study Site 01, Tianjin

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY